Enterprise Value

81.05M

Cash

296.4M

Avg Qtr Burn

-39.79M

Short % of Float

5.82%

Insider Ownership

2.95%

Institutional Own.

93.43%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) Details
Rare diseases, Lung disease, Pulmonary arterial hypertension

Phase 3

Data readout

Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) Details
Lung disease, Pulmonary hypertension associated with interstitial lung disease

Phase 3

Initiation

Failed

Discontinued

GB1275 (Oral CD11b modulator) Details
Solid tumor/s, Esophageal cancer, Cancer, Gastric cancer

Failed

Discontinued

Failed

Discontinued